John Richard Pinion - 18 May 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP, Chief Quality Operations Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
18 May 2023
Net transactions value
-$100,600
Form type
4
Filing time
19 May 2023, 13:54:14 UTC
Previous filing
03 Mar 2023
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $100,600 -2,012 -2.6% $50.00 74,744 18 May 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 Includes 596 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Remarks:

EVP, Chief Quality Operations Officer